Krebs Biochemicals and Industries share price & results
- Jun 2026
- Jun 2026
Andhra Pradesh-based manufacturer of bulk pharmaceutical ingredients (APIs), operating under a related-party manufacturing arrangement with promoter Ipca Laboratories.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 7.0 | +27.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 11.8 | +49.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -2.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Return on equity | 8.70 | −8.1 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -20.04 | +6.5 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | -29.74 | −30.2 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −15.9% 1Y
1Y: ₹70.95 on 24 Oct 2025 → ₹59.64. High ₹71.28 (22 Dec 2025), low ₹39.75 (30 Mar 2026).
- Previous close
- ₹62.22
- Market cap
- ₹135 Cr
- 52-week range
- ₹39.75 – ₹71.28
- One year
- −13.80%
- Return on equity (TTM to Jun 2026)
- 8.70%
Overview
- Symbol
- NSE:KREBSBIO
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Krebs Biochemicals and Industries Limited does
Based on the company's own presentations, annual report and earnings calls.
Krebs Biochemicals & Industries manufactures active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, with commercial production commenced in 1994. Its Unit-I plant at Nellore is currently manufacturing and selling an API, while Unit-II at Kasimkota (Vizag) has been shut since February 2025 under an Andhra Pradesh Pollution Control Board closure order. Much of its manufacturing is done on a loan-license/contract basis for promoter company Ipca Laboratories Limited, which sources APIs, intermediates and job-work manufacturing from Krebs's facilities.
Segments
- Active Pharmaceutical Ingredients (APIs)
- Contract / loan-license manufacturing
- Manufacturing units
- 2 (Unit-I Nellore; Unit-II Kasimkota/Vizag)
- Unit-II (Vizag) operational status
- Non-operational since 9 Feb 2025 (AP Pollution Control Board closure order)
- Commercial production commenced
- 1994
- Unit-II regulatory certification
- EDQM (Europe) accredited and certified
- Unit-I customer qualification
- Audited and approved as a qualified vendor by European customers
- Manufacturing model
- Loan-license / contract manufacturing for promoter Ipca Laboratories Ltd.
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +53% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 11 | 6 | 5 | 4 | 7 | 7 | 7 |
| Expenses | 16 | 16 | 12 | 8 | 7 | 7 | 8 | 6 |
| Operating profit | -3 | -5 | -5 | -2 | -3 | 0 | -1 | 1 |
| Operating margin | −21.1% | −41.1% | −88.7% | −38.1% | −67.2% | 4.1% | −12.6% | 11.8% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Interest | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | -6 | -8 | -8 | -5 | -6 | -3 | -2 | -2 |
| Tax rate | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | -6 | -8 | -8 | -5 | -6 | -3 | -2 | -2 |
| EPS (₹ per share) | -2.67 | -3.59 | -3.84 | -2.47 | -2.85 | -1.45 | -1.09 | -1.15 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 50 | 43 | 24 |
| Expenses | 59 | 58 | 29 |
| Operating profit | -9 | -15 | -5 |
| Other income | 0 | 1 | 2 |
| Interest | 5 | 6 | 7 |
| Depreciation | 7 | 7 | 6 |
| Profit before tax | -20 | -27 | -17 |
| Net profit | -20 | -27 | -17 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves | -97 | -121 | -141 | -168 | -179 | -184 |
| Borrowings | 143 | 183 | 194 | 212 | 219 | 225 |
| Other liabilities | 122 | 91 | 104 | 103 | 106 | 101 |
| Total liabilities | 190 | 175 | 178 | 169 | 168 | 163 |
| Fixed assets | 139 | 147 | 150 | 146 | 146 | 142 |
| Capital work in progress | 8 | 4 | 2 | 3 | 1 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 43 | 24 | 26 | 20 | 20 | 20 |
| Total assets | 190 | 175 | 178 | 169 | 168 | 163 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | -15 | -17 | -25 | 2 | -8 | -2 |
| Cash from investing | -23 | -23 | -13 | -8 | -5 | -4 |
| Cash from financing | 38 | 40 | 37 | 6 | 13 | 6 |
| Net cash flow | 1 | -1 | 0 | 0 | 0 | 0 |
| Free cash flow | -40 | -41 | -36 | -5 | -11 | -5 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 2 | 5 | 4 | 14 | 0 | 0 |
| Inventory days | 234 | 230 | 170 | 543 | 396 | — |
| Days payable | 292 | 340 | 217 | 1051 | 1192 | — |
| Cash conversion cycle | -57 | -106 | -44 | -494 | -795 | 0 |
| Working capital days | -187 | -261 | -232 | -322 | -787 | -1593 |
| Return on capital employed | −40.0% | −57.0% | −29.0% | −19.0% | −30.0% | −15.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Promoters hold 72.74% as of Jun 2026; institutions added 0.00 pts since Mar 2026.
- Promoters 72.74%
- Foreign institutions 0.50%
- Public 26.76%
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 1.86% held
- newly disclosed 1.70% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Krebs Biochemicals and Industries Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 49.65% | unchanged | |
| 12.48% | unchanged | |
| 9.93% | unchanged | |
| 4.81% | unchanged | |
| 1.86% | newly disclosed | |
| 1.70% | newly disclosed | |
| 0.52% | unchanged | |
| 0.11% | unchanged | |
| 0.05% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Krebs Biochemicals and Industries Limited
Free account: one company. Everything above stays public.
Write why you follow Krebs Biochemicals and Industries Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Krebs Biochemicals and Industries Limited
Guides on how to read this kind of business and the numbers that matter.